PCV-13、PCV-15和PCV-20疫苗在哥伦比亚的潜在影响
该研究回顾性分析2015至2019年哥伦比亚波哥大690例侵袭性肺炎球菌病(IPD)患者,比较不同肺炎球菌疫苗的理论血清型覆盖率。结果显示≤5岁儿童中PCV-20覆盖率最高(71.3% [149/209]),18-64岁成人中PCV-20最高(61.8% [164/265]),≥65岁人群中PPSV-23最高(58.1% [100/172])其次为PCV-20(55.2% [95/172])。未覆盖血清型占33.9% [234/690]。
要点
- ≤5岁儿童中PCV-20理论覆盖率最高,为71.3% [149/209]。
- 18-64岁成人中PCV-20覆盖率最高,为61.8% [164/265]。
- ≥65岁人群PPSV-23覆盖率58.1% [100/172],PCV-20为55.2% [95/172]。
核心结论
- 在儿童中引入PCV-20、在成人中引入PCV-20联合PPSV-23加强剂可能降低哥伦比亚全年龄段IPD频率;未来疫苗需纳入未覆盖血清型。
研究设计与样本
- 回顾性分析2015至2019年哥伦比亚波哥大诊断为侵袭性肺炎球菌病(IPD)的患者,共纳入690例,比较不同肺炎球菌疫苗的理论血清型覆盖率并按年龄分层。
主要发现
- ≤5岁儿童中,已批准疫苗中PCV-20理论保护率最高,为71.3% [149/209]。
- 18-64岁成人中PCV-20理论保护率最高,为61.8% [164/265]。
- ≥65岁人群中PPSV-23理论保护率最高,为58.1% [100/172],其次为PCV-20的55.2% [95/172]。
- 未覆盖血清型占队列的33.9% [234/690],最常见的为6C(20.5% [48/234])、15A(12.8% [30/234])和23A(11.5% [27/234])。
临床怎么用
- 作者认为,在儿童中引入PCV-20、在成人中引入PCV-20联合PPSV-23加强剂可能降低哥伦比亚全年龄段IPD频率。
- 作者认为,未来疫苗需要纳入未覆盖的血清型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide information about which pneumococcal vaccine could have greater coverage in Colombia. METHODS: This is a retrospective analysis of patients diagnosed with invasive pneumococcal disease (IPD) between 2015 and 2019 in Bogotá, Colombia. We compared the theoretical serotype coverage of the available anti-pneumococcal vaccines (i.e., PCV-10, PCV-10 SII, PCV-13, PCV-15, PCV-20, PCV-21, PCV24, PPSV-23) and the non-vaccine-covered serotypes stratified by age. RESULTS: 690 IPD cases were included. In children ≤5 y/o, of the approved vaccines PCV-20 showed the most theoretical protection (71.3 % [149/209]), while in adults aged 18-64 y/o was PCV-20 (61.8 % [164/265]), and in those ≥65 y/o was PPSV-23 (58.1 % [100/172]) followed by PCV-20 (55.2 % [95/172]). The non-covered serotypes represented one-third of the cohort (33.9 % [234/690]), being 6C (20.5 % [48/234]), 15A (12.8 % [30/234]), and 23A (11.5 % [27/234]) the most prevalent. CONCLUSION: Introducing PCV-20 for children and PCV-20 along with a PPSV-23 booster in adults may reduce IPD frequency in all ages in Colombia. The inclusion of non-covered serotypes is required for future vaccines.
引用
- Serrano-Mayorga CC, Ibáñez-Prada ED, Restrepo-Martínez JM, et al. The potential impact of PCV-13, PCV-15 and PCV-20 vaccines in Colombia. Vaccine. 2024. PMID: 38336559. doi:10.1016/j.vaccine.2024.01.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。